Literature DB >> 23117382

The splenic artery stump pressure is affected by arterial anatomy after proximal embolotherapy in blunt splenic injury.

Jay Anthony Requarth1, Preston R Miller.   

Abstract

BACKGROUND: Proximal splenic artery embolotherapy can be used as an adjunct to nonoperative management of blunt splenic injury (BSI); however, the hemodynamic changes in the distal splenic artery after proximal splenic artery occlusion are unknown.
METHODS: A retrospective review of 48 patients who underwent transient occlusion of the proximal splenic artery with distal splenic artery pressure measurements was performed. Patients were grouped into those with celiac artery stenosis and those with normal celiac anatomy as determined by contrast-enhanced computed tomography.
RESULTS: Celiac stenosis was identified in 12 (25.0%) of the 48 patients. The celiac stenosis and normal anatomy groups were not statistically different in their systolic pressure, diastolic pressure, mean arterial pressure, age, sex, and splenic injury grade. Transient occlusion of the proximal splenic artery resulted in a decreased distal splenic artery systolic pressure, diastolic pressure, and mean arterial pressure and a decreased systolic and mean perfusion gradient in all patients (42.6 ± 20.8 mm Hg, 39.7 ± 17.8 mm Hg, 40.9 ± 18.9 mm Hg, 67.4 ± 14.5%, and 55.4 ± 17.9%, respectively). The distal splenic artery stump pressure values in the celiac stenosis and normal anatomy patients differed significantly (72.7 ± 32.0 mm Hg vs. 36.7 ± 11.2 mm Hg, 66.6 ± 26.5 mm Hg vs. 34.4 ± 9.3 mm Hg, 69.0 ± 27.9 mm Hg vs. 35.5 ± 10.2 mm Hg, 46.1 ± 19.7% vs. 71.6 ± 8.9%, 28.8 ± 21.6% vs. 60.6 ± 11.7%, for systolic pressure, diastolic pressure, mean arterial pressure, systolic gradient, and mean gradient in celiac stenosis and normal anatomy BSI patients, respectively; all values of p < 0.0001).
CONCLUSION: In hemodynamically stable BSI patients, the systolic pressure in the distal splenic artery is decreased by an average of 67% after proximal splenic artery embolotherapy; however, the pressure reduction in those patients with celiac stenosis is significantly less. This finding may explain some postembolotherapy delayed splenic hemorrhage events. LEVEL OF EVIDENCE: Prognostic/epidemiologic study, level III; therapeutic study, level IV.

Entities:  

Mesh:

Year:  2012        PMID: 23117382     DOI: 10.1097/TA.0b013e3182701e62

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  5 in total

Review 1.  Splenic trauma: endovascular treatment approach.

Authors:  Maxwell Cretcher; Catherine E P Panick; Alexander Boscanin; Khashayar Farsad
Journal:  Ann Transl Med       Date:  2021-07

2.  Anatomy and influence of the splenic artery in laparoscopic spleen-preserving splenic lymphadenectomy.

Authors:  Chao-Hui Zheng; Mu Xu; Chang-Ming Huang; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 3.  The impacts of different embolization techniques on splenic artery embolization for blunt splenic injury: a systematic review and meta-analysis.

Authors:  Jing-Jing Rong; Dan Liu; Ming Liang; Qing-Hua Wang; Jing-Yang Sun; Quan-Yu Zhang; Cheng-Fei Peng; Feng-Qi Xuan; Li-Jun Zhao; Xiao-Xiang Tian; Ya-Ling Han
Journal:  Mil Med Res       Date:  2017-05-30

4.  Emergency treatment of splenic injury in a novel mobile minimally invasive interventional shelter following disaster: a feasibility study.

Authors:  Tianming Yao; Jingjing Rong; Ming Liang; Jingyang Sun; Fengqi Xuan; Lijun Zhao; Xiaozeng Wang; Fei Li; Geng Wang; Yaling Han
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-08-09       Impact factor: 2.953

5.  Morphometric analysis of the splenic artery using contrast-enhanced computed tomography (CT).

Authors:  David J Brinkman; Stephanie Troquay; Wouter J de Jonge; Eric D Irwin; Margriet J Vervoordeldonk; Misha D P Luyer; Joost Nederend
Journal:  Surg Radiol Anat       Date:  2020-10-26       Impact factor: 1.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.